PDE4A and chronic obstructive pulmonary disease: Although roflumilast has achieved significant efficacy in clinical COPD treatment,86, 87 unexpected severe side effects of PDE4 inhibitors such as emesis, diarrhoea, nausea, and psychiatric adverse events cannot be disregarded.88